Content deleted Content added
m Validated CAS and added FDA UNII |
add belantamab mafodotin |
||
Line 76:
| pages=3128–38
| pmc = 4023420
}}</ref> It is part of the approved drug [[belantamab mafodotin]] in [[multiple myeloma]] and some experimental anti-cancer [[antibody-drug conjugate]]s such as [[vorsetuzumab mafodotin]] and [[SGN-CD19A]]. In [[International Nonproprietary Name]]s for MMAF-antibody-conjugates, the name '''mafodotin''' refers to MMAF plus its attachment structure to the antibody.<ref>[http://www.ama-assn.org/resources/doc/usan/mafodotin.pdf Statement on a nonproprietary name adopted by the USAN Council: Mafodotin]</ref>
==Mechanism of action==
| |||
